Product logins

Find logins to all Clarivate products below.


Renal Cell Carcinoma | Treatment Sequencing | US | 2023

Key benefits and uses

Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.

Identify untapped treatment scenarios and key competitors to aid trial design.

Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.

Discover untapped populations to expand product share and drive strategic decisions.

Questions answered

•Where is my product positioned vs. competitors in the treatment journey?

•What are physicians’ most frequent treatment sequences. Who is benefiting and how can I defend my asset’s share and position?

•What are the market-relevant treatment scenarios according to oncology experts?

•Where are the untapped business opportunities that I can capitalize on?

•How can I optimize trial design and ensure a competitive edge for my pipeline asset?

GEOGRAPHY

United States.

PRIMARY MARKET RESEARCH

Survey of 100 U.S. medical oncologists.

Product description

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
Report
Male Hypogonadism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (US)
Male hypogonadism (low testosterone, or low T) is a condition characterized by impaired spermatogenesis and low serum testosterone. Most cases are secondary, driven by aging or comorbidities (e.g…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…